Beniwal Ranjana, Gupta Lalit Kumar, Khare Ashok Kumar, Mittal Asit, Mehta Sharad, Balai Manisha
Department of Dermatology, Venereology and Leprology, AIIMS, Jodhpur, Rajasthan, India.
Department of Dermatology, Venereology and Leprology, R.N.T Medical College, Udaipur, Rajasthan, India.
Indian Dermatol Online J. 2019 Jan-Feb;10(1):27-33. doi: 10.4103/idoj.IDOJ_207_18.
Cutaneous adverse drug reactions (CADRs) are probably the most frequent of all manifestations of drug sensitivity. As a considerable number of new drugs are periodically introduced into the market, the incidence of CADR is likely to increase. The pattern of CADR and the causative drugs is likely to change accordingly. There is no uniformly accepted and reliable method of objectively assessing the causal link between drug and adverse reaction.
To study the clinical patterns and causative drugs and compare causality assessment [World Health Organization (WHO) and Naranjo algorithm] of CADR among patients attending the dermatology department.
This is a cross-sectional hospital-based study in which all patients with suspected CADR attending the dermatology department of a tertiary care center over a 9-month period were evaluated using the causality assessment criteria recommended by the WHO-Uppsala Monitoring Centre (UMC) and Naranjo scale. The severity of the reaction was assessed using Adverse Drug Reaction Severity Assessment Scale (modified Hartwig and Siegel scale).
A total of 200 consecutive patients with CADR were evaluated. The causality assessment for a drug as per WHO scale yielded 63 (31.5%) cases as certain, 12 (6%) as probable, and 125 (62.5%) as possible, whereas Naranjo scale showed 26 (13%) cases to be definite, 138 (69%) as probable, and 36 (18%) as possible. There was poor agreement between the two scales. Fixed drug eruption was the most common pattern of CADR (82.41%). The average number of drugs received by patients was 2.09. The most common suspected drug group was antimicrobials ( = 170; 40.5%), followed by nonsteroidal anti-inflammatory drugs ( = 148; 35.3%) and antiretroviral drugs ( = 41; 9.7%). Fixed drug eruption was most commonly caused by paracetamol. Antiepileptics and antimicrobials were the most common suspects among severe cutaneous adverse reactions.
Multiple concomitant drug usage by patients and inability to provoke all patients/measure drug levels in blood resulted in higher number of drugs with causal association as probable/possible.
WHO-UMC scale was found to be easier to apply and evaluate, with greater practical utility. Poor agreement between the two commonly used scales emphasizes the need for a consistent and uniform causality assessment tool.
皮肤药物不良反应(CADRs)可能是药物敏感性所有表现中最常见的。由于大量新药定期投放市场,CADR的发生率可能会增加。CADR的模式和致病药物可能会相应改变。目前尚无客观评估药物与不良反应之间因果关系的统一认可且可靠的方法。
研究皮肤科就诊患者中CADR的临床模式和致病药物,并比较因果关系评估[世界卫生组织(WHO)和纳兰霍算法]。
这是一项基于医院的横断面研究,对一家三级医疗中心皮肤科9个月期间所有疑似CADR的患者,使用世界卫生组织乌普萨拉监测中心(UMC)推荐的因果关系评估标准和纳兰霍量表进行评估。使用药物不良反应严重程度评估量表(改良的哈特维希和西格尔量表)评估反应的严重程度。
共评估了200例连续的CADR患者。根据WHO量表,药物因果关系评估确定为肯定的有63例(31.5%),很可能的有12例(6%),可能的有125例(62.5%);而纳兰霍量表显示明确的有26例(13%),很可能的有138例(69%),可能的有36例(18%)。两种量表之间的一致性较差。固定性药疹是CADR最常见的模式(82.41%)。患者接受的药物平均数量为2.09种。最常见的可疑药物类别是抗菌药物(=170;40.5%),其次是非甾体抗炎药(=148;35.3%)和抗逆转录病毒药物(=41;9.7%)。固定性药疹最常见的病因是对乙酰氨基酚。抗癫痫药和抗菌药物是严重皮肤不良反应中最常见的可疑药物。
患者多种药物联合使用以及无法对所有患者进行激发试验/测量血液中的药物水平,导致可能/可能存在因果关系的药物数量较多。
发现WHO-UMC量表更易于应用和评估,具有更大的实用价值。两种常用量表之间的一致性较差,强调需要一种一致且统一的因果关系评估工具。